The high mortality rate and frequency of adverse effects associated with Remdesivir ‘begs the question … Why is this the protocol in American hospitals?’ An attorney recently released data showing a remarkably high fatality rate for COVID patients who were prescribed Remdesivir. An attorney recently released data showing a remarkably high fatality rate for COVID patients who were prescribed Remdesivir. According to attorney Thomas Renz, 25.9% of those prescribed Remdesivir for COVID-19 are recorded as having died in the Centers for Medicare & Medicaid Services (CMS) database. CMS data indicated that of 7,960 beneficiaries prescribed Remdesivir for COVID-19, 2,058 beneficiaries died. Forty-six percent of those fatalities occurred within 14 days of Remdesivir treatment. The death rate for COVID patients prescribed Remdesivir dwarfs the fatality rate of COVID patients prescribed Ivermectin, which is recorded by the CMS database as being 7.2%. For the public’s further consideration of Remdesivir’s safety, Renz has pointed out that a Remdesivir Clinical Trial Final Report has shown that about a quarter of patients experienced serious adverse events from the drug. The study, published in the New England Journal of Medicine, showed that “serious adverse events were reported in 131 of the 532 patients who received Remdesivir (24.6%).” Renz noted on his website that this data “has been withheld by the government from our citizens.” He added, “This begs the question … Why is this the protocol in American hospitals? Does this appear ‘safe and effective’ to you?”
If You Find EarthNewspaper.com Informative, Please Make A Contribution
Donate today and support the work I do seven days a week. Each day I publish more than a dozen news articles and videos, from honest, independent and reliable sources, on a completely ad-free website. There are four ways you may donate: credit card, check, bank wire, or SubscribeStar. I, Mark R. Elsis, thank you in advance for your gracious generosity, so that EarthNewspaper.com All The Honest News Fit To Publish may keep growing quickly.